Mendel Money Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mendel Money Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-273	Closed	-$263K	–	134
2024 Q1	$263K	Buy	273 +1	+0.4%	+$951	0.12%	117
2023 Q4	$239K	Sell	272 -18	-6%	-$14.8K	0.11%	121
2023 Q3	$239K	Hold	290	–	–	0.13%	118
2023 Q2	$208K	Hold	290	–	–	0.11%	122
2023 Q1	$238K	Sell	290 -10	-3%	-$7.54K	0.13%	119
2022 Q4	$216K	Sell	300 -4	-1%	-$2.95K	0.12%	118
2022 Q3	$209K	Buy	+304	New	+$191K	0.13%	112
2022 Q2	–	Sell	-307	Closed	-$214K	–	121
2022 Q1	$214K	Buy	+307	New	+$194K	0.1%	120

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Mendel Money Management's REGN Position: Q2 2024 in Review

Mendel Money Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 273 shares — an estimated $263K sold.

Mendel Money Management first reported a position in REGN in Q1 2022 and held it in 8 quarters. The position peaked at $263K in Q1 2024. 1,334 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

Mendel Money Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Mendel Money Management sold 273 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $263K.
Mendel Money Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 8 quarters.
Mendel Money Management's Regeneron Pharmaceuticals position peaked at $263K in Q1 2024.
1,334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Mendel Money Management's 13F filing for Q2 2024, filed 13 Aug 2024.